Neostigmine Bromide
Specifications
114-80-7CAS Number
204-054-8EC Number
[3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium bromideIUPAC Name
C12H19BrN2O2Chemical Formula
303.2 g/molMolecular Weight
neostigmine bromide; 114-80-7; Vagostigmin; Kirkstigmine bromide; Eustigmin bromide; Neoserine bromide; Syntostigmin bromide; neo-Proserin; Proserine bromide; Stigmanol bromide; Synstigmin bromide; Leostigmine bromide; Neostigmini bromidum; Philostigmin bromide; Neo proserine; Bromure de neostigmine; Bromuro de neostigmina; Neostigmine methyl bromide; Neoproserine; DTXSID9041075; (m-Hydroxyphenyl)trimethylammonium bromide dimethylcarbamate; NSC-757233; 3-Dimethylcarbamoxyphenyl trimethyl ammonium bromide; 005SYP50G5; 3-Hydroxyphenyltrimethylammonium bromide dimethylcarbamic ester; DTXCID7021075; CHEBI:179557; Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl-, bromide; [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium;bromide; Benzenaminium, 3-[[(dimethylamino)carbonyl]oxy]-N,N,N-trimethyl-, bromide; (3-(dimethylcarbamoyloxy)phenyl)-trimethylazanium;bromide; Bromide, Neostigmine; RefChem:832351; 204-054-8; 3-((Dimethylcarbamoyl)oxy)-N,N,N-trimethylbenzenaminium bromide; MFCD00011795; 3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium bromide; Neostigmine (Bromide); MLS000028387; SMR000058591; Stigmosan bromide; Prostigmin bromide; Benzenaminium, 3-[[(dimethylamino)carbonyl]oxy]-N,N,N-trimethyl-, bromide (1:1); Prostigmine bromide; Synstigmini bromidum; Vagostigmine bromide; Syntostigmine bromide; 3-(Dimethylcarbamoyloxy)trimethylanilinium ion Bromatum; Synthostigmine bromide; Syntostigmin (tablet); Synstigminbromid; Neostigmina bromuro; Neostigmina bromuro [DCIT]; Neostigmini bromidum [INN-Latin]; NEOSTIGMINEBROMIDE; SR-01000000073; NCGC00163240-01; CAS-114-80-7; EINECS 204-054-8; Bromure de neostigmine [INN-French]; Bromuro de neostigmina [INN-Spanish]; Neoesserin; 114-80-7 (bromide); UNII-005SYP50G5; Eustigmin bromide;Neoserine bromide; Vagostigmin (TN); Prestwick_352; Neostigmine bromide [USP:INN:BAN:JAN]; Neostigmine bromide CRS; Opera_ID_1504; Carbamic acid, dimethyl-, ester with (m-hydroxyphenyl)trimethylammonium bromide; NEO PROSERINE [JAN]; SCHEMBL41128; MLS001146913; orb342006; CHEMBL54126; SPECTRUM1500428; orb2946024; Neostigmine bromide (Prostigmin); NEOSTIGMINE BROMIDE [MI]; SCHEMBL29618009; HMS500I07; HY-B0423R; NEOSTIGMINE BROMIDE [INN]; NEOSTIGMINE BROMIDE [JAN]; LULNWZDBKTWDGK-UHFFFAOYSA-M; Neostigmine (Bromide) (Standard); HMS1569M18; HMS1920P15; HMS2091H18; HMS2096M18; HMS2235J11; HMS3262D13; HMS3372E02; HMS3713M18; Pharmakon1600-01500428; NEOSTIGMINE BROMIDE [VANDF]; HY-B0423; MSK10462; NEOSTIGMINE BROMIDE [MART.]; Neostigmine bromide (JAN/USP/INN); Tox21_112037; Tox21_500816; CCG-39110; EBC-04137; NEOSTIGMINE BROMIDE [USP-RS]; NEOSTIGMINE BROMIDE [WHO-DD]; NEOSTIGMINE BROMIDE [WHO-IP]; NSC757233; s2490; AKOS015895725; AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, BROMIDE, DIMETHYLCARBAMATE; Tox21_112037_1; FN26183; LP00816; NSC 757233; NCGC00015730-11; NCGC00094149-01; NCGC00094149-02; NCGC00094149-03; NCGC00094149-04; NCGC00261501-01; BS-14646; DA-66031; NEOSTIGMINE BROMIDE [EP MONOGRAPH]; MLS-0002855.P042; NEOSTIGMINE BROMIDE [USP MONOGRAPH]; NEOSTIGMINI BROMIDUM [WHO-IP LATIN]; EU-0100816; N0358; N1757; NS00079222; ST50411544; T1624; C08197; C71473; D00995; N 2001; EN300-12576352; F160100; SR-01000000073-3; SR-01000000073-5; SR-01000000073-7; (3-Dimethylcarbamoyloxyphenyl)trimethylammonium Bromide; Q27105147; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-ammonium;bromide; N,N-dimethyl[3-(trimethylamino)phenoxy]carboxamide, bromide; Neostigmine bromide, >=98% (HPLC and titration), powder; (3-Hydroxyphenyl)trimethylammonium Bromide Dimethyl Carbamate; 3-(N,N-Dimethylcarbamoyloxy)-N,N,N,-trimethylanilinium bromide; Neostigmine bromide, European Pharmacopoeia (EP) Reference Standard; Neostigmine bromide, United States Pharmacopeia (USP) Reference StandardSynonyms
